Release date: 2014-06-10
Researchers at many organizations are exploring how to use artificial intelligence and big data to find better treatments for difficult diseases such as cancer. Progress has been made, but they have encountered difficulties in collecting patient information.
Researchers at IBM, Boston Pharmaceuticals Berg Pharma, Memorial Sloan Kettering, UC Berkeley and others are exploring how to use artificial intelligence and big data to find better Disease treatment methods.
However, the biggest challenge in making full use of these computing tools in the medical field is that the massive amounts of data in this area are being shelved – or not digitalized from the start.
Early medical research results or patient medical records are often locked in the files of pharmaceutical companies or in the filing cabinets of doctors' offices.
Patient privacy issues, conflicts of interest between companies, and a pure lack of electronic medical records hinder information sharing in the medical field, making every treatment like an isolated event. If information sharing in the medical field is progressing, people are likely to find more general treatment options.
Michael Keiser, a lecturer at the University of California, San Francisco, points out that when you can analyze clinical trial data, genomic data, and electronic medical records for 100,000 patients, compared to information that was previously only accessible to a small number of patients. You will be able to discover treatment options that were previously undetectable.
Given this prospect, some organizations are beginning to integrate medical data together.
At the end of last year, the American Society of Clinical Oncology (ASCO) announced the initial progress of its "CancerLinQ" project. "CancerLinQ" is a "fast learning system" that allows researchers to access, access and analyze the medical records of anonymous cancer patients.
In April of this year, a non-profit organization with a number of major pharmaceutical companies, the CEO Roundtable on Cancer, announced the launch of the Project Data Sphere.
The program will create a third-stage cancer clinical trial data sharing and analysis platform. The initial data set has been developed by AstraZeneca, Bayer, Celgene, Memorial Sloan-Kettering Cancer Center, Pfizer, Sanofi, etc. Provided together.
These data have removed the patient's personal information and have been uniformly numbered for free use by life science companies, hospitals, medical institutions, and independent researchers. They can access the analysis tools built into the platform or insert data into their own software.
Martin Murphy, chief executive of the Cancer CEO Roundtable, said the PDS program could help identify lesser-known cancer candidates that may have some effect on certain cancers. In a particular study, these drugs may be abandoned because they did not meet the primary goals of the study.
Other efforts to promote information sharing in the medical field include: Global Alliance for Genomics and Health, and European Bioinformatics Research Institute (EMBL-) from multi-medical institutions, research universities, life sciences companies, etc. EBI) maintains a molecular biology database and the Biomarker Consortium established by the National Institute of Health (NIH).
At the same time, Flatiron Health, a startup that uses big data to serve the oncology industry, completed a $130 million Series B round of financing last month, led by Google Ventures, a Google-listed venture capital firm. Flatiron Health has created an OncologyCloud that extracts and integrates clinical data and medical cost data from patient electronic medical records (EMRs).
The system makes sense in data that remains in unsustainable and unstructured formats in doctor's offices and hospitals, enabling analysis of the treatment of large-scale cancer patient populations. Ideally, it can find out which treatment is effective for which types of cancer patients.
Flatiron Health co-founder Nat Turner said: "Flatiron Health focuses on clinical data for so-called 'real world' patients. In the United States, only 4% of cancer patients participate in prospective clinical trials, so we are Efforts to extract and integrate data from the remaining 96% of patients."
He said: "To really understand what is effective for cancer, what kind of treatment other patients are undergoing, and what results have been achieved in cancer research, institutions should open "de-identified" medical data and A typical case of anonymity, this is part of Flatiron Health's vision."
Privacy risk
To be sure, the promotion of medical information should be very cautious. Medical information is highly sensitive, so any privacy risk needs should be carefully considered.
The extent to which medical information can be opened depends on the concessions made by society as a whole. Many people firmly hold the view that saving lives is the most important. But influenced by old habits and outdated rules and regulations, society is not changing fast enough. David Patterson, a computer science professor at the University of California at Berkeley, is deeply touched. Patterson is dedicated to machine learning tools for cancer research.
He said: "For researchers in the computer field, we are used to Internet time and Moore's Law. But now we can't get the official agreement, so that we can collect data and integrate it in a lot of fast food, which is very frustrating."
He pointed out: "Patients' privacy is important, but it's also important to make progress in the field of cancer treatment. The benefit of bringing together a lot of treatment information is that we can make progress in tackling this terrible disease."
None of the experts interviewed can cite the breakthroughs in computing technology such as big data so far. After all, these technologies are new, and the medical data sets have just been integrated, and clinical trials will take years.
But almost everyone agrees that researchers are on the verge of a major breakthrough in cancer treatment.
Murphy said that if the cancer is compared to a mountain, it is near the edge of the peak, and this height is unprecedented.
Source: Fresh Network
Mom and Baby Health Care ( Invisible )
JIAMAI a completely owned subsidiary of Albert Novosino, in charge of the global trade business.
Albert Novosino is a state-of-the-art clinical and also electronic devices company, have more than 100 patents and over 50 FDA signed up products. Albertnovosino is market leader in several niche markets.
Main items including Pressure infusor bag, High blood pressure cuff, Oral Health Care products, Enema system, Otology medical care system, Nasal medical care system, Massagers and Reliever products, Recovery physiotherapy items, Cleaning and Sterilizating devices, etc.
We are a B2B provider and also have a direct acquisition shop on Amazon.
In each sector, there are matching superior products.
Otology medical care system, we have a hot marketing Electric Ear Washing Device.
Nasal healthcare system, we have fully grown Electric Nasal Irrigator as well as Electric Nasal Aspirator.
Enema system, Silicone Enema Bag, Bulb, Bucket that fulfills the requirements of the clinical market, at the same time very popular.
Invite to consult us for even more designs and also personalized services.
Baby Nasal Aspirator, Manual Breast Pump, Manual Inverted Nipple Corrector
Ningbo Jiamai Internet Technology CO., Ltd. , https://www.jmcuhyd.com